Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model. Asian J Androl 2010;12: 308-14.Lopez-Barcons LA. Small-cell neuroendocrine carcinoma of the prostate:are heterotransplants a better experimental model[J].Asian Journal of Andrology,2010,(03):...
Effective treatments for de novo and treatment-emergent small cell/neuroendocrine (t-SCNC) prostate cancer represent an unmet need for this disease. Using metastatic biopsies from advanced cancer patients, we demonstrate that delta-like ligand 3 (DLL3) is expressed in de novo and t-SCNC and is...
Unusual and underappreciated: small cell carcinoma of the prostate Semin Oncol (2007) P.A. di Sant’Agnese et al. Neuroendocrine differentiation in prostatic malignancy Cancer (1996) R.E. Wenk et al. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia Cancer (1977) J. Cheri...
Strange MD Presenter AMA PRA Category 1 Credits™: 1.00 ARRT Category A+ Credits: 0.00 Course Description: This didactic session will focus on the important diagnostic imaging findings of and management implications for neuroendocrine malignancies, mesothelioma, thymoma and other thoracic neoplasms less...
discovered that sEV protein TSP1 is a highly sensitive and non-invasive biomarker for diagnosing neuroendocrine prostate cancer (NEPC) [135]. Additionally, another report showed that plasma sEV CLD3 has a good diagnostic value in distinguishing PCa patients with a Gleason score ≥ 8 from ...
After attending this session, the learner will be able to more accurately diagnosis these non-small cell thoracic malignancies and provide crucial imaging information which will impact patient care. 1. Describe and differentiate the typical imaging manifestations of the various neuroendocrine malignancies....
SCLC: small cell lung cancer. PRAD: prostate adenocarcinoma. PRAD norm: prostate adenocarcinoma adjacent normal tissue. CRPC: castration resistant prostate cancer. SCNPC: small cell neuroendocrine prostate cancer. (C) Average gene expression of selected SCNPC-associated proteins and markers. (D) ...
Mechanistically, KDM6A normally maintains an active chromatin state that favours the ASCL1 subtype with its loss decreasing H3K4me1 and increasing H3K27me3 at enhancers of neuroendocrine genes leading to a cell state that is primed for ASCL1-to-NEUROD1 subtype switching. This work identifies ...
Treatment with the combination of the investigational oral innate immune activator BXCL701 and pembrolizumab led to a median overall survival of 13.6 months in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate ca
Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer Cancer Res., 83 (2) (2023), pp. 301-315, 10.1158/0008-5472.Can-22-1433 View in ScopusGoogle Scholar Collins et al., 2004 B.J. Collins, W. Kleeberger, D.W. Ball Notch in lung development...